Skip to main content

Table 2 Best tumor response according to the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1

From: Modified FOLFIRINOX versus gemcitabine plus oxaliplatin as first-line chemotherapy for patients with locally advanced or metastatic cholangiocarcinoma: a retrospective comparative study

  mFOLFIRINOX (n = 27)
N (%)
Gemox (n = 22)
N (%)
p value
Complete response 0 (0) 0 (0)
Partial response 9 (33.3) 5 (22.7)
Stable disease 12 (44.4) 9 (40.9)
Progressive disease 6 (22.2) 8 (36.4)
Objective response rate 9 (33.3) 5 (22.7) 0.530
Disease control rate 21 (77.8) 14 (63.5) 0.276